CA
NZ
UK
AU
IND
US
…
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Income before tax | -68.87M | -66.81M | -34.05M |
| Net income | -68.87M | -66.81M | -34.05M |
| Selling general administrative | 20.03M | - | - |
| Gross profit | 11.61M | 5.71M | 4.00M |
| Reconciled depreciation | 1.39M | - | - |
| Ebit | -81.07M | -66.77M | -33.99M |
| Ebitda | -79.68M | -65.49M | -32.99M |
| Depreciation and amortization | 1.39M | 1.29M | 1.00M |
| Operating income | -81.07M | -70.01M | -37.85M |
| Other operating expenses | 94.07M | 77.01M | 42.85M |
| Interest expense | 0.01M | 0.03M | 0.06M |
| Interest income | 3.32M | - | - |
| Net interest income | 3.32M | - | - |
| Total revenue | 13.00M | 7.00M | 5.00M |
| Total operating expenses | 92.68M | 75.73M | 41.85M |
| Cost of revenue | 1.39M | 1.29M | 1.00M |
| Total other income expense net | 12.20M | 3.20M | 3.80M |
| Net income from continuing ops | -68.87M | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Total assets | 224.95M | 76.06M | 82.25M |
| Other current assets | 4.28M | 1.95M | 0.95M |
| Total liab | 19.38M | 220.29M | 159.96M |
| Total stockholder equity | 205.57M | -144.24M | -77.71M |
| Other current liab | 9.56M | 15.70M | 4.33M |
| Common stock | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | - | - |
| Retained earnings | -221.09M | -152.22M | -83.91M |
| Cash | 44.06M | 16.25M | 29.02M |
| Total current liabilities | 17.91M | 27.98M | 6.86M |
| Current deferred revenue | - | 3.00M | - |
| Net debt | -42.00M | 177.06M | 121.61M |
| Short term debt | 0.59M | 1.02M | 0.77M |
| Short long term debt total | 2.06M | 193.31M | 150.63M |
| Other stockholder equity | 426.65M | 7.98M | 6.20M |
| Total current assets | 153.48M | 73.99M | 80.03M |
| Long term investments | 67.49M | 0.00M | - |
| Short term investments | 105.14M | 55.78M | 50.06M |
| Accounts payable | 7.76M | 8.26M | 1.76M |
| Non currrent assets other | 0.10M | 0.06M | 0.04M |
| Non current assets total | 71.47M | 2.07M | 2.22M |
| Capital lease obligations | 1.71M | 1.02M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Investments | -115.07M | - | - |
| Total cashflows from investing activities | -115.31M | -3.99M | -48.43M |
| Net borrowings | -0.37M | - | - |
| Total cash from financing activities | 220.76M | 49.42M | 63.75M |
| Net income | -68.87M | -66.81M | -34.05M |
| Change in cash | 27.81M | -12.77M | 29.02M |
| Begin period cash flow | 16.25M | 29.02M | - |
| End period cash flow | 44.06M | 16.25M | 29.02M |
| Total cash from operating activities | -76.44M | -58.20M | -29.97M |
| Issuance of capital stock | 65.23M | - | - |
| Depreciation | 1.39M | 1.29M | 1.00M |
| Other cashflows from financing activities | -1.22M | -0.42M | -0.23M |
| Capital expenditures | 0.23M | 0.09M | 0.12M |
| Change in working capital | -4.12M | 7.42M | 3.34M |
| Stock based compensation | 5.86M | - | - |
| Other non cash items | -4.84M | -0.10M | -0.26M |
| Free cash flow | -76.68M | -58.28M | -30.09M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| EVMN Evommune, Inc. |
0.28 4.40% |
6.65 | - | - | 36.26 | 1.36 | 18.58 |
| NVO Novo Nordisk A/S |
0.01 0.02% |
40.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Luis C. Pena | Founder, President, CEO & Director | 1963 |
| Dr. Eugene Andrew Bauer M.D. | Co-Founder, Chief Medical Officer & Director | 1942 |
| Dr. Jeegar Patel Ph.D. | Chief Scientific Officer | 1978 |
| Ms. Janice Drew M.P.H. | Chief of Development Operations | 1963 |
| Dr. Lou Sehl Ph.D. | Senior Vice President of Technical Operations | NA |
| Dr. Daniel J. Burge M.d. | Senior Vice President of Clinical Development | 1962 |
| Mr. J. Mark Jackson M.D. | Senior Vice President of Clinical Development | NA |
| Mr. Kyle Carver CPA, M.B.A. | Chief Financial Officer | 1988 |
| Mr. Gregory S. Moss Esq. | Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer | 1984 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...